MedTrace Logo

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2016-06-21

No results posted yet for this study

Summary

RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.

PURPOSE: This phase I trial is to study the safety and effectiveness of radiolabeled octreotide in treating children who have advanced or refractory solid tumors.

Conditions

Interventions

RADIATION

90Y-DOTA-tyr3-OCTREOTIDE

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • O'Dorisio, M S

    lead OTHER

Principal Investigators

  • M. Sue O'Dorisio, MD, PhD · Holden Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00049023 on ClinicalTrials.gov